

56th OOG MEETING



19-22 OCT | 2022

Crowne Plaza Beach Hotel, Tel Aviv

הפקולטה לרפואה
ע"ש סאקלר
אוניברסיטת תל אביב



Local Hosts:

Dr. Vicktoria Vishnevskia-Dai

Prof. Didi Fabian

Dr. Ofira Zloto

Wednesday 19th | October 2022

08:30-09:00	Welcome Reception and Registration
09:00-09:20	Meeting Opening: Dr. Vicktoria (Vicky) Vishnevskia-Dai, Head of Israel Ocular Oncology Group (IOOG) Welcome from OOG BOARD Main Sponsors Greetings Prof. Arnon Afek, Director of Genreal Sheba Medical center Prof. Anat Loewenstein, Head of the Israeli Ophthalmological Society
09:30-12:00	YIN Meeting
09:30-09:35	Introduction: Natasha Van Poppelen
09:35-10:25	Research Techniques: Zebra Fish
10:25-10:50	Short overview of research techniques used in Ocular Melanoma
10:50-11:20	Coffee Break and Exhibition
11:20-11:50	OOG Keynote lecture 1: From Idea to Therapy Prof. Gal Markel , MD PhD, MBA, Deputy Director General, Rabin MC at Clalit Health Services, Tel Aviv University
11:50-12:00	YIN closure
12:00-13:30	OOG 1: Intraocular Tumors
12:00-12:12	Moderators: Horgan N., Rospond-Kubiak I., Eiger-Moscovich M., Fabian D.. Choroidal Hemangioma in Pregnancy and Post-Partum: A Case Series Andron A. A. , Gushansky k, Fabian D. I., Vishknevskia-Dai V.
12:12-12:24	Surgical options to treat complicated retinal hemangioblastomas Veckeneer M. , Van Overdam K., Bartoszek P.

12:24-12:36	In silico feasibility study: Retinal blood vessels organoid model to study retinal hemangioblastomas Bals K. , Hajjaj A., Brands T., de Klein A., Kilic E., Brosens E.
12:36-12:48	Retinal Vaso Proliferative Tumors Coman A. , Murtagh P., Punic G., Horgan N.
12:48-13:00	Mammalian target of Rapamycin Inhibitors for the treatment of Astrocytic Hamartoma in Tuberous Sclerosis Complex (TSC) Vorobichik Berar O. , Tzadok M., Zloto O., Moroz I., Hecht I., Ampaire Musika A., Schlomovitz O., Fabian I.D, Vishknevskia-Dai V.
13:00-13:12	Choroid metastases from primary lung adenocarcinoma - A case series O'Brien L. , P. Murtagh, N. Horgan
13:12-13:24	Intraocular metastases from Cutaneous Melanoma Lemaitre S. , Thaug C., Sagoo M.
13:24-13:30	Metastatic retinal lymphoma secondary to conjunctival MALT lymphoma with transformation into DLCL Grishina E. , Andryukhina O.
13:30-13:42	Spontaneous growth of presumed epi-papillary astrocytic hamartoma Weinberger Y. , Dotan G., Gal-Or O.

13:42-14:30 Lunch Break at Hotel Restaurant

14:30-14:50 OOG Keynote lecture 2: CAR T Cell Therapy in Pediatric Oncology and Future Perspectives for Ocular Oncology

Dr. Elad Jacoby, Division of Pediatric Hematology and Oncology, Sheba MC, Tel Aviv University

14:50-16:50 Updates in Ocular Oncology:

Moderators: V. Vishnevskia-Dai, D. Fabian

14:50-14:55 **Introduction**

Sponsored By:

14:55-15:15 **Uveal Melanoma: Cassoux N.**



15:15-15:35 **Ocular Surface Squamous Neoplasia and Conjunctival Lymphoma: Heegaard S.**

15:35-15:55 **Intraocular Lymphoma: Pe'er J.**

15:55-16:15 **Retinoblastoma: Munier F**

16:15-16:35 **Conjunctival Melanoma: Moulin A.**

16:35-16:50 **Discussion**

17:30 Departure from conference hotel lobby

18:00-20:00 Social Event

Location: Peres Center for Peace and Innovation* - Cocktail and Guided Tour
Honorary Achievements Prof Mordechai Rosner and Prof Jacob Pe'er
Dr. Vicktoria (Vicky) Vishnevskia-Dai, Israel Ocular Oncology Group
Prof. Arnon Afek, Sheba MC
Dr. Amir Elhalal, Ophthalmology, Sheba MC
Prof. Itay Chowers, Hadassah University MC

*Includes outbound transportation from the conference' hotel to Peres Center in Jaffa.
At the end of the event - free evening and independent arrival to the hotels.

08:30-09:00 **Welcome Reception and Registration**

09:00-10:24 **OOG 2: Uveal melanoma**

Moderators: Pefkianaki M., Moulin A., Frenkel S.

09:00-09:12 **Impact of Fitzpatrick Skin Type on Metastatic Risk from Uveal Melanoma in 854 Consecutive Patients at a Single Center**

Negretti G., Bayasi F., Goldstein S., Omega M., Taylor O., Ni R., Chiang L., Kim R., Lien E., Barke M., Shields C.

09:12-09:24 **Secondary Primary Cancers (SPC) in a Polish Cohort of Patients with Uveal Melanoma. Rospond-Kubiak I.**, Wroblewska-Zierhoffer M., Kubiak A.

09:24-09:36 **Non-Invasive testing in UM patients using Circulating Tumor DNA and shallow whole genome sequencing**

van Poppelen N.M., de Bruyn D.P., Vaarwater J., Brands T., de Klein A., Brosens E., Kilic E.

09:36-09:48 **Blood Plasma Metabolomics to Support Uveal Melanoma Diagnosis**

Brossens E., de Bruyn D., Bongaerts M., Bonte R., Vaarwater J., Meester-Smor M.A., Verdijk R., Paridaens D., Naus N.C., de Klein A., Ruijter G.J.G, Kilic E.

09:48-10:00 **The prognostic value of chromosome 8q gain in SF3B1-mutated Uveal Melanoma**

Nguyen J.Q.N., Vaarwater J., Verdijk R., de Klein A., Kilic E., Brossens E.

10:00-10:12 **A retrospective comparative analysis of genetic factors in groups of patients with and without metastases of Uveal Melanoma**

Yarovaya V., Yaroyov A., Zaretsky A., Levashov I., Chudakova L.

10:12-10:24 **Multimodal approach in detection of predictors for transformation in Melanocytic Intraocular Tumors**

Saakyan S.V., Myakoshina E.B., Khlgatyan M.R., Tsygankov A.Y., Burdennyi A.M., Loginov V.I.

10:24-11:00 **Coffee Break and Exhibition**

11:00-12:24 **OOG 3: Uveal melanoma**

Moderators: N. Cassoux, U. Pfeffer, V. Vishenvskia-Dai, J. Pe'er.

11:00-11:12 **FOXD1 is involved in Uveal Melanocyte development and associated with high-risk Uveal Melanoma**

Van den Bosch Q., Nguyen J.O.N., Brands T., van den Bosch T.P.P, Verdijk R., Paridaens D., Naus N.C., de Klein A., Kilic E., Brosens E.

11:12-11:24 **Do we need three Uveal Melanoma Cell Types for prognostication?**

Yarovoy A., Yarovaya V., Zaretsky A., Levashov I., Shatskih A.

11:24-11:36 **Retinal vascular changes following proton beam Radiotherapy in Choroidal Melanoma**

Eibenberger K., Hussain R., Asterios D., Heinmann H.

11:36-11:48 **Proton beam irradiated retino-invasive Uveal Melanomas**

Moulin A., Zografos L., Schalenbourg A.

11:48-12:00 **Cerivastatin synergizes with trametinib and enhances its efficacy in the therapy of Uveal Melanoma**

Pfeffer U., Amaro A., Tanda E.T., Spagnolo F., Gangemi R., Croce M.

12:00-12:12	Combined treatment of Juxta & Parapapillary Choroidal Melanoma Amiryan A. G. , Saakyan S.V.
12:12-12:24	Long-term follow-up of Circumscribed Iris Melanomas treated by proton beam therapy Cassoux N. , Matet A., Dendale R., Malaise D., Lumbruso-Le Rouic L.
12:24-12:36	Characteristics of Iris Amelanotic Lesions – A Ten-Year Perspective Shemesh R. , Dror S., Vishknevskia-Dai V.
12:36-13:10	OOG Keynote lecture 3: New treatment options for advanced Uveal Melanoma Dr. Ronnie Shapira Frommer - Director of the Ella Institute for Immuno-Oncology and Melanoma, Sheba MC
13:10-14:10	Lunch Break at Hotel Restaurant
14:10-16:30	OOG 4: Retinoblastoma Moderators: Stathopoulos C., Hadjistilianou D, Caspi S., Fabin D.
14:10-14:22	Favorable clinical outcome of familial retinoblastoma after early postnatal screening, diagnosis, and management Malaise D. , Matet A., Lumbruso-Le Rouic L., Levy C., Gauthier-Villars M. Aerts I., Doz F., Cassoux N.
14:22-14:34	Familial Retinoblastoma: variations in clinical presentation and management based on material Vs. paternal inheritance Eiger-Moscovich M. , Ruben M., Dockery Ph., Yaghy A., Shields C.
14:34-14:46	Retinoblastoma in the mosaic form of RB1 gene mutation Ushakova T. , Yugai O., Kozlova V., Mikhailova S., Polyakov V.
14:46-14:58	Lesions simulating retinoblastoma: Pseudoretinoblastomas: the spectrum of pathology and frequency in different age groups. Volodin D. P. , Yaroyov A. A., Yarovaya V. A., Kotelnikova A.V.
14:58-15:10	Malignant transformation of retinocytoma Yarovoy A. , Yarovaya V. A.,Kozlova V.M., Ushakova T.L., Kotelnikova A.V.
15:10-15:22	Long-term efficacy and safety of intravitreal chemotherapy for vitreous seeding in retinoblastoma Stathopoulos C. ,Beck-Popovic M., Munier F.L.
15:22-15:36	Long term results of organ preserving treatment of retinoblastoma in different years Saakyan S.V. , Tadevosyan S.S.
15:36-15:48	Ru-106 plaque brachytherapy for retinoblastoma at Hadassah- 26 years of experience Kubosky S. , Pe'er J., Eiger-Moscovich M., Frenkel S.
15:48-16:00	Results and risk factors of complications of Ru-106 and Sr-90 brachytherapy of retinoblastoma based on 15-year single center experience Yarovoy A. , Yarovaya A.V., Chocheva A.M., Volodin D.P.
16:00-16:12	Thermotherapy in children with Retinoblastoma: Approaches and long-term results Volodin D.P. , Yaroyov A.A, Yarovaya V.A.

16:12-16:24	Primary silicone orbital prosthesis implantation in patients with Retinoblastoma Kotelnikova A., Yaroyov A.V., Ushakova T.L., Yarovaya A.V.
16:24-16:30	Extraocular retinoblastoma: intracranial retinoblastoma involving the visual tract Ushakova T., Polyakov V., Rodina A.
16:30-17:00	Coffee Break and Exhibition
17:00-18:30	A joint session OOG, Israel Ocular Oncology group and the Israel Uveitis Group: Ocular malignant masquerade syndrome. Case gallery
	Moderators: Habot-Wilner Z., Zloto O.
17:00-17:05	introduction
17:05-17:17	Hypopion more than meets the eye Habot-Wilner Z.
17:17-17:29	Optic Disc Swelling in a child Eiger-Moscovich M.
17:29-17:41	Retunoblastoma masquerade Fabian .I.D
17:41-17:53	Primary Vitreoretinal Lymphoma Frenkel. S
17:53-18:05	Ocular Malignant Masquerade Syndrome over view and case gallery Vishnevskia-Dai V.
18:05-18:30	Discussion
	Free Evening

08:30-09:00	Welcome Reception and Registration
09:00-10:00	OOG Business Meeting - Members Only
10:00-11:35	OOG 5: Ocular Adnexal Tumors and Systemic Therapy
	Moderators: S. Heegaard, R. Verdijk , A. Prael, R. Shapira Formmer
10:00-10:12	miR-196b-5p and mir-107 Expression differentiates Ocular Sebaceous Carcinoma from Squamous Cell Carcinoma of the Conjunctiva de Keizer R.O.B. , Vriends A.L.M, Hötte J.H., Paridaens D., Wiemer E.A.C, Verdijk R.
10:12-10:24	Viral and genomic drivers of carcinomas arising in the conjunctiva and lachrymal drainage system Heegard S. , Viera F., Toft P.B., von Buchwald C., Funding M., Ramberg L.
10:24-10:36	The use of electroporation in the treatment of Conjunctival Melanoma Kapelushnik N. , Abdelkader A., Blum S., Sharabi S., Fabian D.I.
10:36-10:48	Lacrimal system and sinonasal recurrence of conjunctival melanoma: A case series Green F. , Lemaitre S., Thaung C., Sagoo M.
10:48-10:58	Systemic management of Conjunctival Sqamous Cell Carcinoma with orbital extension: case repot and review of literature Sergenti J. , Lanza F.B., Guzzo M., Angi M.
10:58-11:10	Periorbital Solitary Plasmacytoma Vs. Multiple Myeloma: presentation and outcomes Zloto O. , Vahdani K., Stack R., Verity D.H., Rose G.E.
11:10-11:22	Checkpoint inhibitor immune therapy-ophthalmic sides effects. Graeff E. , Meyer P.
11:22-11:34	Ocular Melanoma of Unknown Origin: Atypical Uveal or Late Isolated Metastasis of Cutaneous Melanoma. Arazi M. , Fabian D. I.
11:34-11:46	Eyelid specimen comparison, ophthalmology vs plastics departments Levinkron O. , Briscoe D.
11:46-12:00	Quick Coffee
12:00-12:30	OOG Keynote lecture 4: Treatment of advanced eyelid and Conjunctival Melanoma Dr. Ronnie Shapira Frommer - Director of the Ella Institute for immuno-oncology and melanoma. Sheba MC
	Sponsored By:  MSD INVENTING FOR LIFE
12:30-13:00	OOG Keynote lecture 5: Maus x Machina. The role of 3D printing in facial reconstruction. Dr. Vardizer Yoav , Oculoplastics, Bnai Zion MC.
13:00-13:45	Lunch at Hotel Restaurant
13:45	Departure to the desert trip - Meet at Conference Hotel Lobby

56th OOG MEETING



19-22 OCT | 2022

Crowne Plaza Beach Hotel, Tel Aviv



Thanks to the Supportive Companies

Main Sponsors



Sponsors

